{"filings":[{"id":482079,"accession_number":"0001193125-26-227875","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2026-05-18T11:15:07+00:00","items":["8.01"],"status":"ready","headline":"Design Therapeutics reports positive Phase 1/2 data for DT-216P2 in Friedreich ataxia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["After 4 weeks at 1 mpk, mFARS improved 6.4 points, Upright Stability Score 2.7 points, fatigue >5 points (PROMIS).","Whole blood FXN mRNA increased 65% (p<0.001); muscle FXN mRNA up 42% (p=0.015); FXN protein increased 22-27%.","DT-216P2 well-tolerated; no serious adverse events or discontinuations; mild-moderate transient ALT elevations in 3 patients.","Company plans to pursue registrational path; update expected in Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95628,"accession_number":"0001193125-26-187012","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Design Therapeutics Q1 net loss $17.6M; cash $222.8M funds ops into 2029; pipeline on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.6M for Q1 2026; R&D expense $14.4M, G&A $5.3M.","Cash, equivalents and securities total $222.8M as of March 31, 2026, providing runway to 2029.","DT-216P2 Phase 1/2 RESTORE-FA trial dosing continues; frataxin update expected H2 2026.","DT-168 Phase 2 FECD trial ongoing with data in H2 2026; DT-818 DM1 Phase 1 MAD trial to begin dosing H1 2026.","David Shapiro, M.D., appointed to board of directors in March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95627,"accession_number":"0001193125-26-137861","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Design Therapeutics appoints Dr. David Shapiro to Board as Class III director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. David Shapiro appointed to Board effective Mar 31, 2026, as Class III director with term through 2027 annual meeting.","Receives annual cash retainer of $40k for Board service and $5k for Nominating Committee service.","Received initial option grant of 60k shares (3-year monthly vest) and prorated annual option of 7.5k shares (1-year vest).","Also appointed to the Nominating and Corporate Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108829,"accession_number":"0001193125-26-098474","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics reports Q4 2025 net loss of $16.0M; cash $219.8M funds operations into 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 net loss $69.8M; R&D expenses $59.1M, G&A $20.3M.","Cash, equivalents and securities $219.8M as of Dec 31, 2025; runway into 2029.","DT-216P2 (FA) RESTORE-FA trial ongoing; frataxin data expected H2 2026.","DT-168 (FECD) Phase 2 biomarker trial data anticipated H2 2026.","DT-818 (DM1) Phase 1 MAD trial dosing expected H1 2026; results in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108828,"accession_number":"0001193125-26-031772","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Design Therapeutics board member Deepa Prasad resigns effective Feb 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Deepa Prasad resigned from Design Therapeutics Board of Directors effective February 1, 2026.","Resignation due to conflict-avoidance policies associated with her new role at a major bank.","No replacement or other board changes announced; remaining directors continue in office."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125276,"accession_number":"0001193125-25-266933","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics plans DT-818 DM1 trial H1 2026; Q3 net loss $17M; cash $206M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["DT-818 nominated as DM1 development candidate; >90% reduction in toxic RNA foci in preclinical studies.","Ex-US regulatory clearance obtained; Phase 1 MAD trial in Australia to start H1 2026; splicing data expected 2027.","Q3 2025 net loss $17.0M; R&D expense $14.6M; G&A expense $4.7M.","Cash and securities $206.0M as of Sept 30, 2025, supporting pipeline advancement.","Board appointed Justin Gover (former CEO of GW Pharma, led $7B acquisition by Jazz) in September 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142002,"accession_number":"0001807120-25-000004","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Design Therapeutics director resigns; Justin Gover appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Arsani William, M.D. resigned from board effective Sept 9, 2025, not due to any disagreement.","Board appointed Justin Gover as Class III director with term ending at 2027 annual meeting.","Gover also named chair of Compensation Committee.","Gover receives annual cash retainers of $40,000 for board service and $12,000 as committee chair.","Gover granted initial option for 30,000 shares vesting over 3 years and prorated grant of 15,833 shares vesting over 1 year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142001,"accession_number":"0000950170-25-105008","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Design Therapeutics Q2 net loss $19.1M; FDA clinical hold on DT-216P2 US IND; cash $216.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.1M for Q2 2025; R&D expense $15.7M, G&A $5.8M; cash and securities $216.3M as of June 30, 2025.","Early human PK data for DT-216P2 shows favorable translation from NHPs; improved AUC and sustained plasma levels vs DT-216P1.","FDA placed clinical hold on DT-216P2 US IND over starting dose; company plans to address with clinical/nonclinical data; RESTORE-FA trial continues outside US.","Phase 2 biomarker trial of DT-168 in Fuchs Endothelial Corneal Dystrophy patients has been initiated.","Preclinical DM1 program on track for development candidate selection in H2 2025; Huntington's disease preclinical characterization ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159958,"accession_number":"0000950170-25-085380","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Design Therapeutics stockholders elect directors and ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Heather Berger, Ph.D., Rodney Lappe, Ph.D., and John Schmid elected as Class I directors to serve until 2028 annual meeting.","Rodney Lappe received 32,799,677 votes for, 9,948,461 withheld, indicating notable opposition.","Ernst & Young LLP ratified as independent auditor for FY2025 with 53,577,053 votes for, 2,731 against, 1,795 abstentions.","A total of 56,768,678 shares were outstanding and entitled to vote as of the April 15, 2025 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159957,"accession_number":"0000950170-25-065613","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics Q1 net loss $17.7M; cash $229.7M funds into 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expenses $15.4M, G&A $5.0M for Q1 2025; net loss $17.7M.","Cash and securities $229.7M as of March 31, 2025; expected runway into 2029.","Phase 1 SAD trial ongoing for DT-216P2 (FA); MAD patient study planned mid-2025.","Favorable Phase 1 data for DT-168 (FECD); Phase 2 biomarker trial planned H2 2025.","Appointed Chris Storgard, M.D., as Chief Medical Officer in April 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178293,"accession_number":"0000950170-25-035909","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics Q4 2024 net loss $13.7M; cash $245.5M; FA and FECD trials advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.7M for Q4 2024 and $49.6M for full year 2024; R&D expense $44.4M, G&A $18.0M.","Cash, equivalents and securities $245.5M as of Dec 31, 2024; expected funding into 2029.","FA program: Phase 1 single ascending dose trial of DT-216P2 initiated; patient dosing expected mid-2025.","FECD program: DT-168 Phase 1 dosing complete; data on track for H1 2025; observational study enrolled ~250 patients.","DM1 development candidate selection expected in 2025; HD preclinical work ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178292,"accession_number":"0000950170-25-004612","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Design Therapeutics updates corporate presentation with no material new information","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation filed as Exhibit 99.1 for use in investor meetings.","No financial results, clinical data, or guidance changes disclosed in the filing.","Filing includes only the presentation; no other material events reported.","This is a routine Regulation FD disclosure without specific new facts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194942,"accession_number":"0000950170-24-123289","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics Q3 net loss $13.0M; FECD Phase 1 trial initiated, data H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.0M for Q3 2024; R&D expense $11.9M, G&A expense $4.4M.","Cash and securities $254.1M as of Sep 30, 2024; expected to fund operations into 2029.","FECD DT-168 Phase 1 trial initiated in healthy volunteers; initial data expected H1 2025.","FA DT-216P2 Phase 1 single ascending dose study in healthy volunteers on track for H1 2025.","Preclinical programs advancing toward development candidate selection in HD and DM1."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211231,"accession_number":"0000950170-24-090332","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics Q2 net loss $11.8M; cash $261M; FA and FECD programs on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.8M for Q2 2024; R&D expense $10.5M, G&A expense $4.5M.","Cash, cash equivalents and marketable securities $261.0M as of June 30; runway into 2029.","FA program DT-216P2 on track to start patient trials in 2025 after GLP studies complete.","FECD program DT-168 to begin Phase 1 in healthy volunteers in 2024; 200-patient observational study ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229786,"accession_number":"0000950170-24-074243","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Design Therapeutics stockholders elect Pratik Shah as Class III director, ratify EY auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pratik Shah, Ph.D. elected as Class III director with ~42.8M votes for, ~3.5M withheld (7.7M broker non-votes).","Ernst & Young LLP ratified as independent auditor for FY2024 (53,981,806 for, 2,764 against, 2 abstentions).","Annual Meeting held June 13, 2024; 56,495,039 shares outstanding and entitled to vote as of record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229785,"accession_number":"0000950170-24-055645","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics Q1 net loss $11.1M; cash $270.7M; advancing DT-216P2, DT-168, HD, DM1 programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.1M for Q1 2024; R&D expenses $9.8M, G&A expenses $4.6M.","Cash and securities $270.7M as of March 31, 2024; expected funding into 2029.","DT-216P2 for Friedreich Ataxia: GLP studies by year-end 2024; patient trials start 2025.","DT-168 for FECD: Phase 1 development expected to start in 2024; observational study enrolling 200 patients.","GeneTAC pipeline: HD and DM1 programs advancing toward development candidates; preclinical data showed mutant gene knockdown."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}